Drug intelligence / Profile preview

propofol + lidocaine

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Small Molecules
Administration: Intravenous

Overview

LSI-102 is a pre-mixed intravenous combination of the sedative-hypnotic propofol and the local anesthetic lidocaine, developed by LipoSeuticals. It is intended for the induction and maintenance of general anesthesia. The formulation is designed to address the clinical challenge of pain on injection, a frequent side effect of propofol, by incorporating lidocaine directly into the lipid-based emulsion. This reformulation aims to improve patient comfort and streamline the administration process in clinical settings compared to the reference product, Diprivan.

Other names: Pre-mixed propofol-lidocaine comboPropofol-lidocaine combination

Targets

NaV (Voltage-gated sodium channels)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on propofol + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + lidocaine.

Explore the full profile